Introduction {#s1}
============

Focal segmental glomerulosclerosis (FSGS) is a progressive glomerular disease with scarring that occurs secondary to podocyte injury.^[@R1],[@R2]^ Loss, damage, and detachment of podocytes induced by a series of causes result in the obstruction of capillary lumina by the matrix in part (segmental) of the glomerular capillaries in a portion (focal) of glomeruli.^[@R1],[@R3]^ The podocyte injury might be the consequence of several insults such as hyperglycemia and insulin signaling, circulating permeability factors, genetic factors, mechanical stretch, angiotensin II, calcium signaling, viral infection, chronic pyelonephritis, toxins, drug use, and immunological injury,^[@R4]-[@R7]^ or other unknown mechanisms. These insults might either induce primary (approximately 80% of cases) or secondary FSGS (remaining 20%). The widely studied cause of the primary form of FSGS is circulating permeability factors that are mostly composed of soluble urokinase plasminogen-activator receptor (suPAR),^[@R8]^ cardiotrophin-like cytokine-1 (CLC-1),^[@R5]^ and angiopoietin-like-4 (Angptl4).^[@R9]^ The genes whose mutation may induce FSGS are related to slit diaphragm, actin cytoskeleton or foot process-GBM interaction.^[@R7]^ These susceptible genes include NPHS1,^[@R10]^ NPHS2,^[@R11]^ PLCE1,^[@R12]^ WT1,^[@R13]^ LAMB2,^[@R14]^ PTPRO,^[@R15]^ ARHGDIA,^[@R16]^ ADCK4,^[@R17]^ TRPC6, ^[@R18]^ and APOL1.^[@R19]^

This podocytopathy mostly presents with proteinuria and some characteristics of nephrotic syndrome including hypoalbuminemia, hypercholesterolemia, and peripheral edema.^[@R20]^ The diagnostic gold standard for FSGS is histopathologic features in kidney biopsy, which elucidate the segmental glomerular scares, tubular changes, and hypertrophy in light microscopy and podocyte microvillous transformation, foot process effacement, and tubuloreticular inclusions in electron microscopy.^[@R21]^ Ever since the first presentation of FSGS by Arnold Rich in 1959,^[@R22]^ many studies have been conducted to identify the impaired biological processes, molecular pathways, and non-invasive diagnostic and prognostic biomarkers for FSGS.^[@R23]-[@R26]^ Nevertheless, the pathogenic pathways of FSGS especially in the primary form are still under investigation.

An in silico study of FSGS by our research group revealed the involvement of several pathways in the pathogenesis of FSGS including "chondroitin sulfate degradation" and "eicosanoid metabolism".^[@R23]^ Based on this result, we designed an experiment for confirming the hypothesis of impairment of these 2 important pathways in the development of FSGS. Four important enzymes involved in these pathways were targeted for investigation: arylsulfatase and N-acetylglucosaminidase (also known as hexosaminidase) for chondroitin sulfate degradation pathway, and cyclooxygenase-2 (COX-2) and prostaglandin I2 synthase for eicosanoid metabolism pathway. The potential diagnostic role of the target genes was also examined.

Methods {#s2}
=======

Sample collection and preparation {#s2-1}
---------------------------------

Urine samples were collected from 20 biopsy-proven FSGS patients and 17 healthy volunteers, and urine sediment was acquired by centrifugation at 14 000 g at 4°C for 8 minutes. All the samples were stored at -80°C until use. The disease of patients was diagnosed as primary glomerulonephritis and subjects with secondary diseases and other complications such as diabetes and malignancies were excluded. The healthy volunteers were confirmed based on common laboratory tests.

RNA extraction and reverse transcription {#s2-2}
----------------------------------------

RNA isolation from urine sediment samples was performed using RNX-Plus (Cinnagen, Tehran, Iran) according to the manufacturer's protocol. RNA quality was determined through purity and concentration measurements using WPA spectrophotometer (Biochrom) and genomic DNA contamination was removed using DNase I (RNase-free) (Thermo Scientific, Waltham, MA, USA).

Total RNA extracted from urine sediment samples was reverse transcribed using RevertAid First Strand cDNA Synthesis kit (Thermo Scientific, Waltham, MA, USA). Based on the protocol provided by the manufacturer, the mixture of the random hexamer, oligo (dT) primers and other appropriate reagents were prepared in the final volume of 20 μL. Synthesis of cDNA was performed with 0.3 μg of the isolated mRNA as a template at 42°C for 60 minutes, 25°C for 5 minutes, and 42°C for 60 minutes. The reaction was then terminated at 70°C for 5 minutes. The cDNA was stored at −80°C.

Quantitative real-time reverse-transcription polymerase chain reaction {#s2-3}
----------------------------------------------------------------------

All primers were designed using AlleleID 6 software (see [Supplementary file 1, Table S1](#Suppl1){ref-type="supplementary-material"}) and synthesized by Macrogen (Macrogen, South Korea). A 20 µL of the mixture of the following components was used for mRNA quantification: 10 μL RealQ Plus 2X Master Mix Green (Ampliqon, Denmark), 1 μL first-strand cDNA template, 0.8 μL of each primer of target genes (arylsulfatase, hexosaminidase, COX-2, prostaglandin I2 synthase), and distilled water. Parameters of thermocycling were 15 minutes at 95°C for enzyme activation followed by 35 cycles of 95°C for 20 seconds and termination at 60°C for 60 seconds using Rotor-Gene Q instrument (Qiagen). Expression levels of mRNAs were normalized against the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Relative expression of genes was calculated using 2^−∆Ct^ method.

Statistical analysis {#s2-4}
--------------------

Non-parametric Mann--Whitney U-test was used to compare different variables (relative expression of target genes) between the patient and control groups and between the subgroups of patients based on the range of proteinuria and estimated glomerular filtration rate (eGFR). Correlation between target genes and clinical and pathological characteristics in the patient group was assessed using Spearman's rank correlation. These clinical and pathological features were eGFR, serum creatinine, proteinuria, interstitial fibrosis and tubular atrophy (IFTA), interstitial inflammation, glomerular sclerosis, and mesangial hypercellularity. To assess and compare the diagnostic role of target genes in the study groups, receiver operating characteristic (ROC) analysis was performed and the areas under the curves (AUC), sensitivity, and specificity were calculated. Combination of target genes as a diagnostic panel for ROC analysis was carried out using multiple logistic regression. Linear regression analysis was also performed to compare the ability of target genes in the prediction of eGFR and proteinuria. All data were presented as median and range. *P* value \< 0.05 was considered significant. R program version 3.4.3.3 was used for the statistical analysis.

Results {#s3}
=======

Patients and controls {#s3-1}
---------------------

Patients were included in this study after pathologic diagnosis by kidney biopsy. The patients were subdivided into 2 groups based on the level of proteinuria and renal function status (i.e. eGFR). Accordingly, 12 patients had nephrotic-range proteinuria (\>3 g/d), eight patients had sub-nephrotic-range proteinuria (\< 3 g/d), 12 patients had eGFR \< 60 (m/min/1.73 m^2^), and eight patients had eGFR \> 60 (m/min/1.73 m^2^). [Table 1](#T1){ref-type="table"} shows the demographic and clinical information of patients and healthy subjects. The patients and healthy groups were adjusted based on sex and age to reduce their confounding effects.

###### Demographic and clinical data of patients and healthy individuals

  ------------------------ --------------------- --------------------
                           **Patients (n=20)**   **Healthy (n=17)**
  Age (y)                  48 (23-82)            49 (25-55)
  Men                      12 (40%)              8 (47%)
  BUN (mg/dL)              21.49 (9.34-45.32)    21 (8.9-23)
  SCr (mg/dL)              1.31 (0.7-3.09)       0.9 (0.7-1.2)
  Chol (mg/dL)             200.5 (192-292)       178 (85-192)
  TG (mg/dL)               179 (72-363)          138 (75-149)
  HDL (mg/dL)              46 (36-64)            73 (39-86)
  LDL (mg/dL)              112 (53-183)          121 (73-129)
  FBS                      103 (70-110)          93 (80-108)
  Proteinuria (mg/24h)     1785 (700-19695)      \-
  eGFR (m/min/1.73 m^2^)   50 (20-115)           85 (51-102)
  ------------------------ --------------------- --------------------

Abbreviations: eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen; SCr, serum creatinine; Chol, cholesterol; TG, Triglyceride; HDL, high-density lipoprotein cholesterol; LDL, Low-density lipoprotein cholesterol; FBS, fast blood sugar.

*Note*: Data are presented as median (range). Percentage of men in each pathologic group is presented in parenthesis.

Evaluation of gene expression changes between patients and healthy individuals {#s3-2}
------------------------------------------------------------------------------

The comparison of every single gene between patients and healthy subjects was not significant ([Table 2](#T2){ref-type="table"}), and the AUC was poor, however, the ROC analysis for the combination of three target genes (hexosaminidase, arylsulphatase, COX-2) improved the diagnosis of patients group to 76% (Fig. S1). The expression level of prostaglandin I2 synthase was lower than the limit of detection in real-time polymerase chain reaction (RT-PCR) in the urine sediment and therefore its comparison with other genes in diagnosis was not possible. The panel of these three genes could diagnose the patients from healthy individuals with a sensitivity of 82% and specificity of 67%. The details of the diagnostic evaluation of each gene separately and in combination are shown in [Table 2](#T2){ref-type="table"}. The descriptive comparison of the expression level of these genes between patients and healthy subjects is depicted in [Fig. 1](#F1){ref-type="fig"}.
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###### The ROC analysis results for the diagnosis of FSGS patients from control subjects based on each target gene alone and in combination

  ---------------------------------------- ----------------- ----------------- ---------
  **Gene**                                 **Specificity**   **Sensitivity**   **AUC**
  Arylsulfatase                            53%               62%               0.57
  Hexosaminidase                           95%               24%               0.55
  COX-2                                    87%               42%               0.6
  Arylsulfatase + Hexosaminidase           42%               87%               0.65
  Arylsulfatase + Hexosaminidase + COX-2   67%               82%               0.76
  ---------------------------------------- ----------------- ----------------- ---------

Evaluation of target genes and their effects on disease progression in patients {#s3-3}
-------------------------------------------------------------------------------

To confirm the value of our target genes and pathways in progression of FSGS, we investigated these genes in patients considering 2 clinical factors: range of proteinuria (\>3 g/d (nephrotic-range) and \< 3 g/d (sub-nephrotic-range)) and eGFR (\> 60 mL/min/1.73 m^2^ and \< 60 mL/min/1.73 m^2^). The results indicated that the expression level of hexosaminidase was significantly higher in the urinary sediment of patients with nephrotic-range proteinuria compared to the sub-nephrotic group (*P* value = 0.02 and fold change =3.7) ([Fig. 2](#F2){ref-type="fig"}). In addition, the combination of target genes could improve the prediction of disease severity based on protein excretion by 87% (with sensitivity and specificity of 77% and 100% respectively) in comparison to every single gene alone. The result of ROC analysis for the patients in 2 groups of nephrotic- and sub-nephrotic-range proteinuria is summarized in [Table 3](#T3){ref-type="table"}. The ROC curves are depicted in Fig. S2.

![](bi-9-89-g002){#F2}

###### The results of ROC analysis and U-test for discrimination of patients with nephrotic and sub-nephrotic proteinuria

  ---------------------------------------- ----------------- ----------------- ---------
  **Gene**                                 **Specificity**   **Sensitivity**   **AUC**
  Arylsulfatase                            54%               100%              0.74
  Hexosaminidase                           75%               100%              0.81
  COX-2                                    70%               50%               0.55
  Arylsulfatase + Hexosaminidase           72%               100%              0.78
  Arylsulfatase + Hexosaminidase + COX-2   77%               100%              0.87
  ---------------------------------------- ----------------- ----------------- ---------

The expression level of target genes based on eGFR was not significantly different in the patients with mild decline of renal function (eGFR \> 60 mL/min/1.73 m^2^) compared to severe decline of renal function (eGFR \< 60 mL/min/1.73 m^2^) ([Fig. 3](#F3){ref-type="fig"}), however, the panel of combination of these target genes predicted the patients with severe disease with AUC of 74% (with sensitivity and specificity of 60% and 90%, respectively) ([Table 4](#T4){ref-type="table"}). The ROC curves are depicted in Fig. S3.
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###### The results of ROC analysis of target genes for discrimination of patient groups with different eGFR levels (\< 60 and \> 60 mL/min/1.73 m^2^)

  ---------------------------------------- ----------------- ----------------- ---------
  **Gene**                                 **Specificity**   **Sensitivity**   **AUC**
  Arylsulfatase                            17%               100%              0.46
  Hexosaminidase                           85%               41%               0.57
  COX-2                                    50%               100%              0.58
  Arylsulfatase + Hexosaminidase           50%               83%               0.6
  Arylsulfatase + Hexosaminidase + COX-2   60%               90%               0.74
  ---------------------------------------- ----------------- ----------------- ---------

The correlation analysis indicated a significant positive association between hexosaminidase and proteinuria. There was also a significant positive correlation between COX-2 and interstitial inflammation, while a negative correlation was observed between COX-2 and serum creatinine ([Table 5](#T5){ref-type="table"}).

###### Correlation analysis of target genes with clinical and histopathological features in the patients group

  ------------------ ----------------------- ------------------------------- ----------------------- ---------------------------- -------------------------- ----------------------- --------------------------------
                     **Proteinuria**         **Interstitial inflammation**   **eGFR**                **Serum creatinine level**   **Glomerular sclerosis**   **IFTA**                **Mesangial hypercellularity**

  Arylsulphatase     r = 0.4, *P* = 0.17     r = 0.009, *P* = 0.97           r = 0.025, *P* = 0.94   r = -.026,\                  r = -0.05,\                r = 0.087, *P* = 0.72   r = -0.22,\
                                                                                                     *P* = 0.92                   *P* = 0.85                                         *P* = 0.38

  Hexosaminidase     r = 0.58,*P* = 0.03\*   r = -0.08, *P* = 0.75           r = 0.08, *P* = 0.79    r = 0.072,\                  r= 0.6,\                   r = 0.3, *P* = 0.19     r = -0.025,\
                                                                                                     *P* = 0.77                   *P* = 0.8                                          *P* = 0.91

  Cyclooxygenase-2   r = -0.1, *P* = 0.78    r = 0.53, *P* = 0.035\*         r = -0.19,*P* = 0.7     r = -0.58,\                  r = 0.18,\                 r = 0.039, *P* = 0.89   r = 0.03,\
                                                                                                     *P* = 0.019\*                *P* = 0.5                                          *P* = 0.91
  ------------------ ----------------------- ------------------------------- ----------------------- ---------------------------- -------------------------- ----------------------- --------------------------------

Abbreviations: eGFR, estimated glomerular filtration rate; IFTA, interstitial fibrosis/tubular atrophy.

The linear regression analysis revealed the importance of COX-2 in the prediction of eGFR in the patients (*P* value = 0.005).

Discussion {#s4}
==========

Chondroitin sulfate is one of the major molecules of glycosaminoglycans (GAGs), and consists of repetitive disaccharide units of N-acetylgalactosamine.^[@R27]^ GAGs are complex linear anionic carbohydrates which are found on cell surfaces or in the extracellular matrix, and play important roles in cell growth, differentiation, morphogenesis, cell migration, and infection.^[@R27],[@R28]^ The most important enzymes in sulphation and degradation of chondroitin sulphates are arylsulphatase and hexosaminidase that were strongly significant in our previous study.^[@R23]^ In the present study, we examined the hypothesis of the involvement of chondroitin sulfate degradation pathway by evaluating the expression level of these 2 enzymes in the urine sediment of patients with FSGS. Our results indicated a significant increase in the level of hexosaminidase expression in patients with nephrotic compared with sub-nephrotic proteinuria ([Fig. 2](#F2){ref-type="fig"}). The same trend was observed in the expression level of arylsulfatase, however, the *P* value was not significant. Correlation analysis also revealed a positive correlation between hexosaminidase expression level and proteinuria in the patients ([Table 5](#T5){ref-type="table"}). These findings indicate the importance of these 2 target enzymes from chondroitin sulfate degradation pathway in the progression of FSGS. Since GAGs are known as renoprotective molecules against the progression of renal diseases,^[@R29]^ whose function is important in preservation of integrity, thickness, and permselectivity of the endothelial glycocalyx,^[@R30],[@R31]^ one can postulate that degradation of GAGs (and especially chondroitin sulfate) by activation of enzymes such as arylsulfatase and hexosaminidase could damage the protective GAGs and end up with proteinuria and renal injury. This finding is in line with that of a study by Hultberg et al who showed the importance of hexosaminidase in proteinuric diseases,^[@R32]^ however, our results are proposed for the first time in FSGS and in the sediment of urine.

COX-2 (also known as prostaglandin G/H synthase 2) is one of the most important enzymes in the production procedure of eicosanoids,^[@R33]^ that is induced by inflammatory mediators and mitogens, and hence plays a key role in pathophysiologic processes.^[@R34]^ It is well characterized that prostaglandins (one type of eicosanoids that are produced by COX-2), especially prostaglandin I2 (PGI2), act locally on the glomerulus and derive from COX-2 expressed in the macula densa.^[@R35]^ Therefore, their function is important for the homeostasis of the renal condition, and their perturbation contributes to the pathogenesis of renal vascular hypertension through stimulating renal renin synthesis and release.^[@R36]^ COX-2 is also highly inducible in podocytes, mesangial cells, renal tubular epithelial cells, and interstitial cells,^[@R37]^ and plays important roles in the kidney such as regulating renin release,^[@R38]^ water/salt metabolism,^[@R39],[@R40]^ and kidney development.^[@R41],[@R42]^ Perturbation in the metabolism of eicosanoids particularly under the influence of COX-2 and PGI2 synthase were also shown to be important in the pathogenesis of FSGS in our previous in silico study.^[@R23]^ The experiment on mRNA level of COX-2 in this study showed a non-significant decrease in FSGS patients compared to control subjects ([Fig. 1](#F1){ref-type="fig"}), whereas no signal was detected for prostaglandin I2 synthase. This decrement of COX-2 expression is in line with the studies of Morham et al, Norwood et al and Dinchuk et al, which suggested COX-2 deficiency could induce renal abnormalities and development of nephropathy in experimental models.^[@R43]-[@R45]^ In spite of these findings, there are contradictory studies on the pathologic effect of the increase of COX-2 expression in renal diseases such as diabetic nephropathy,^[@R46]^ and accordingly COX-2 inhibitor drugs are suggested for reducing proteinuria and effects of renal dysfunction.^[@R47],[@R48]^

Altogether it seems that COX-2 plays a complicated role in renal pathophysiology which highly depends on situation, tissue, and etiology of the disease. For instance, downregulation of COX-2 in certain conditions along with other factors might end up with FSGS, while upregulation of COX-2 in the presence of other pathologic factors develops diabetic nephropathy. In general, this finding beside significant correlation of COX-2 with serum creatinine level and interstitial inflammation ([Table 5](#T5){ref-type="table"}) and significant regression with eGFR, unravels the pathologic role of COX-2 in the progression of FSGS. Furthermore, ROC analyses revealed that combination of arylsulphatase, hexosaminidase, and COX-2 has a better ability in the diagnosis of patients from healthy controls, as well as diagnosis of patients with more severe disease than those with single genes ([Tables 2](#T2){ref-type="table"}-[4](#T4){ref-type="table"}). Therefore, this panel of genes could be considered as non-invasive biomarker candidates for FSGS. The high AUCs of this triple panel in discrimination of patients with higher proteinuria and severe decline of eGFR shows that these genes along with each other could be more effective in the progression of the disease.

Conclusion {#s5}
==========

In conclusion, it is confirmed the role of chondroitin sulfate degradation and eicosanoids mechanism in the pathogenesis of FSGS, and therefore, a panel of three biomarker candidates is suggested for non-invasive diagnosis of this disease.
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Research Highlights {#s12}
===================

What is the current knowledge? {#Res1}
------------------------------

1.  √ The pathways of chondroitin sulfate degradation and eicosanoid metabolism contribute to FSGS pathogenesis and progression of this disease.

2.  √ A panel of three enzymes including arylsulfatase, hexosaminidase, and cyclooxygenase-2 is sensitive to the non-invasive diagnosis of FSGS.

What is new here? {#Re2}
-----------------

1.  √ Cyclooxygenase-2 has a significant relationship with clinical (i.e. serum creatinine and eGFR) and histological features (i.e. interstitial inflammation) of patients with FSGS and hence is a valuable target for further analyses on the level of protein in the larger cohort.
